ProKidney Corp.
rilparencel
chronic kidney disease (CKD)
Resolved
371days ago
Advisory committee · ~ Jul 1, 2025 estimated
What's at stake
An FDA advisory committee reviews rilparencel for chronic kidney disease (CKD) around ~ Jul 1, 2025. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 16h ago
“July 2025 Type B meeting: FDA confirmed that eGFR slope in patients from the ongoing PROACT 1 study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission under the accelerated approval pa”